^
    5ms
    HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial. (PubMed, Cancer Med)
    HS-10352 at 6 mg QD was well-tolerated in patients with HR-positive, HER2-negative ABC, and showed preliminary antitumor activity in patients with PIK3CA mutated tumors. These findings support the further clinical development of HS-10352.
    P1 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    HS-10352
    over1year
    A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=224, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation
    |
    fulvestrant • HS-10352
    almost2years
    Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=54, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Apr 2021 --> Apr 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    HS-10352
    over3years
    Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=54, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    HS-10352